Reckitt Benckiser (LON:RB) has been assigned a GBX 6,400 ($85.87) price objective by Barclays in a research note issued on Thursday. The brokerage presently has a “neutral” rating on the stock. Barclays’ price objective suggests a potential upside of 10.82% from the stock’s previous close.
RB has been the topic of a number of other research reports. Berenberg Bank set a GBX 7,500 ($100.63) price objective on Reckitt Benckiser and gave the company a “buy” rating in a report on Tuesday, February 20th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and issued a GBX 7,200 ($96.61) price objective on shares of Reckitt Benckiser in a report on Thursday, March 8th. Citigroup reaffirmed a “buy” rating and issued a GBX 7,200 ($96.61) price objective on shares of Reckitt Benckiser in a report on Wednesday, February 28th. Sanford C. Bernstein set a GBX 8,100 ($108.68) price objective on Reckitt Benckiser and gave the company a “buy” rating in a report on Monday, April 23rd. Finally, Goldman Sachs Group lowered their price objective on Reckitt Benckiser from GBX 7,000 ($93.92) to GBX 6,400 ($85.87) and set a “neutral” rating on the stock in a report on Monday, February 19th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the stock. Reckitt Benckiser has a consensus rating of “Hold” and an average price target of GBX 7,038.70 ($94.44).
Shares of RB opened at GBX 5,775 ($77.49) on Thursday. Reckitt Benckiser has a twelve month low of GBX 5,562 ($74.63) and a twelve month high of GBX 8,110.43 ($108.82).
In related news, insider Christopher Sinclair acquired 809 shares of the business’s stock in a transaction that occurred on Friday, May 25th. The stock was purchased at an average cost of GBX 6,030 ($80.91) per share, for a total transaction of £48,782.70 ($65,453.78). Also, insider Rakesh Kapoor sold 120,000 shares of Reckitt Benckiser stock in a transaction that occurred on Friday, May 4th. The stock was sold at an average price of GBX 5,576 ($74.82), for a total value of £6,691,200 ($8,977,861.26).
About Reckitt Benckiser
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.
Receive News & Ratings for Reckitt Benckiser Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser and related companies with MarketBeat.com's FREE daily email newsletter.